28/07/2023 - Press release
Cannabis use disorder (CUD) affects over 14 million individuals in the US.? Despite the urgent need, there are no FDA-approved medications to treat CUD; behavioral treatments have shown limited benefit. AEF0117 is the first of a new pharmacologic class, type 1 cannabinoid receptor signaling-specific inhibitors (CB1-SSi), with a unique mechanism of action and greater safety and efficacy than prior generations of CB1 inhibitors.? In a phase 2a clinical study in volunteers with CUD, AEF0117 produced statistically significant reductions in the positive subjective and reinforcing effects of smoked cannabis.
15/06/2023 - Press release
A study published in iScience, spearheaded by the Hospital del Mar Research Institute and the Barcelonaβeta Brain Research Centre, part of the Pasqual Maragall Foundation, validates these tools for monitoring potential sufferers. Data was analysed from 56 volunteers who participated in the PENSA study, designed to determine whether it is possible to slow cognitive decline in stages prior to the onset of dementia through a combination of a lifestyle intervention programme and the consumption of a preparation based on a green tea component. It was possible to monitor the evolution of the cognitive functions of these people much more closely and continuously than with standard tests. This paves the way for the adaptation, practically in real time, of treatments that can be adjusted to changes in cognitive decline.
02/12/2022 - Press release
The Hospital del Mar Medical Research Institute is leading the study that will evaluate whether a new molecule can be used to improve the cognitive performance of people with Down syndrome. The study is part of the ICOD project for the improvement of cognition in Down syndrome, promoted by the European Union, which is funding a project of this type for the first time. The treatment has already passed the trial phase with volunteers without Down syndrome, which sought to certify the safety and tolerability of the medicine. In this new phase, the safety of the treatment in people with Down syndrome will be validated and the first indications of effectiveness will be obtained. It is estimated that results may be available by mid-2023.
16/11/2022 - Press release
A study led by the Hospital del Mar Medical Research Institute, the Barcelonaβeta Brain Research Centre (BBRC), a research unit from the Pasqual Maragall Foundation, and the University of Gothenburg, has compared the validity of nine biomarkers for the day-to-day diagnosis of Alzheimer's disease in hospital centres. The work involved a cohort of patients from Hospital del Mar with various neurological pathologies. The researchers analysed the presence of nine variants of the Tau protein in blood samples from these people. Some of these blood markers are just as useful for detecting Alzheimer's as those measured in the reference test used, namely the analysis of cerebrospinal fluid obtained by lumbar puncture. Less invasive plasma biomarker determinations than those performed after a lumbar puncture may provide a tool for improving the diagnosis of Alzheimer's disease and determining which individuals should undergo further testing to confirm the diagnosis. The work has been published in the leading journal in this field, Alzheimer's & Dementia.
03/11/2022 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute links psychological trauma in childhood with an increased risk of developing some kind of mental disorder years later. This is the first study to analyse the relationship between psychological trauma and various mental pathologies at a transdiagnostic level. It examines fourteen already published reviews or meta-analyses, involving more than 90,000 participants. The study is published in the European Archives of Psychiatry and Clinical Neuroscience and demonstrates the need to study the history of patients suffering from a mental disorder.
11/08/2022 - Press release
The research, led by the Barcelonaβeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the University of Gothenburg, has been published in the prestigious journal Nature Medicine. The study, which used data from almost 400 participants of the ALFA+ Study, which has the impetus of the "la Caixa" Foundation, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms. The results of this research make p-tau231 a very promising blood biomarker to detect early those middle-aged people who show the first brain changes associated with Alzheimer's and to conduct clinical trials aimed at this early stage of Alzheimer's.
12/04/2022 - Press release
COVID-19 has accelerated the need to raise awareness of the psychological well-being of the human teams that form part of SME organisations, in the face of the economic uncertainty aggravated by the war in Ukraine.
17/02/2022 - Press release
New research associates the presence of Caudovirales in gut microbiota to an improvement in cognitive functions and memory in humans, mice and flies. The results show that bacteriophages present in the gut microbiota influence the relationship between the microbiome and the brain The article, published in the journal Cell Host & Microbe, was led by Dr. Jordi Mayneris-Perxachs and Dr. José Manuel Fernández-Real, of the Nutrition, Eumetabolism and Health group of the Girona Biomedical Research Institute (IDIBGI) Dr. Josep Trueta and CIBEROBN, and has been carried out in collaboration with the Neuropharmacology research group led by Dr. Rafael Maldonado of Pompeu Fabra University and attached to the Hospital del Mar Medical Research Institute (IMIM); the FISABIO Foundation, the University of Valencia (UV) and the University of Alicante (UA).
02/12/2021 - Press release
A study using mice shows that animals fed a diet rich in beneficial live microorganisms suffer less from the addictive effects of alcohol consumption. The work has been published in the journal Frontiers in Nutrition. It is the first to analyse the possible relationship between intestinal bacteria and the possibility of altering addictive behaviours related to alcohol use. In the study, animals that maintain a healthy microbiota also avoid addiction relapse and have lesser effects from associated disorders such as depression and anxiety.
According to a study by the Hospital del Mar Medical Research Institute and the Germans Trias i Pujol Institute of Health Sciences published in the International Journal of Neuropsychopharmacology, driving after drinking alcohol mixed with energy drinks can give the driver a false sense of security, thus increasing the chances of driving while intoxicated and suffering an accident Due to their high caffeine content, energy drinks reduce the sedative effect of alcohol, despite not affecting its negative effects on driving ability Moreover, combining the two drinks increases blood concentrations of alcohol and caffeine. Researchers warn that these effects may favour alcohol intoxication in people with a lower tolerance to these drinks
Més informació "Mixing energy drinks with alcohol can increase the risk of a traffic accident"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
